Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021

Author:

Tenforde Mark W.,Patel Manish M.,Gaglani Manjusha,Ginde Adit A.,Douin David J.,Talbot H. Keipp,Casey Jonathan D.,Mohr Nicholas M.,Zepeski Anne,McNeal Tresa,Ghamande Shekhar,Gibbs Kevin W.,Files D. Clark,Hager David N.,Shehu Arber,Prekker Matthew E.,Erickson Heidi L.,Gong Michelle N.,Mohamed Amira,Johnson Nicholas J.,Srinivasan Vasisht,Steingrub Jay S.,Peltan Ithan D.,Brown Samuel M.,Martin Emily T.,Monto Arnold S.,Khan Akram,Hough Catherine L.,Busse Laurence W.,Duggal Abhijit,Wilson Jennifer G.,Qadir Nida,Chang Steven Y.,Mallow Christopher,Rivas Carolina,Babcock Hilary M.,Kwon Jennie H.,Exline Matthew C.,Botros Mena,Lauring Adam S.,Shapiro Nathan I.,Halasa Natasha,Chappell James D.,Grijalva Carlos G.,Rice Todd W.,Jones Ian D.,Stubblefield William B.,Baughman Adrienne,Womack Kelsey N.,Rhoads Jillian P.,Lindsell Christopher J.,Hart Kimberly W.,Zhu Yuwei,Naioti Eric A.,Adams Katherine,Lewis Nathaniel M.,Surie Diya,McMorrow Meredith L.,Self Wesley H.,Calhoun Nicole,Murthy Kempapura,Herrick Judy,McKillop Amanda,Hoffman Eric,Zayed Martha,Smith Michael,Kindle Ryan,Kozikowski Lori-Ann,De Souza Lesley,Ouellette Scott,Thornton-Thompson Sherell,Mehkri Omar,Ashok Kiran,Gole Susan,King Alexander,Poynter Bryan,ten Lohuis Caitlin,Stanley Nicholas,Hendrickson Audrey,Caspers Sean,Tordsen Walker,Kaus Olivia,Scharber Tyler,Jorgensen Jeffrey,Bowers Robert,King Jennifer,Aston Valerie,Rothman Richard E.,Ali Harith,Nair Rahul,Karow Sarah,Robart Emily,Maldonado Paulo Nunes,Khan Maryiam,So Preston,Krol Olivia,Martinez Jesus,Zouyed Zachary,Acosta Michael,Bazyarboroujeni Reihaneh,Jung Haeun,Reddy Raju,Zhang Richard,Gordon Alexandra Jun,Levitt Joe,Perez Cynthia,Visweswaran Anita,Roque Jonasel,Chandrasekaran Sukantha,Angeles Los,Frankel Trevor,Angeles Los,Garner Omai,Angeles Los,Goff Jennifer,Huynh David,Jensen Kelly,Driver Conner,Carricato Michael,Chambers Ian,Nassar Paul,Stout Lori,Sibenaller Zita,Walter Alicia,Mares Jasmine,Pfannenstiel Spenser,Gershengorn Hayley,McSpadden EJ,Truscon Rachel,Thomas Lara,Bielak Ramsay,Valvano Weronika Damek,Fong Rebecca,Fitzsimmons William J.,Blair Christopher,Gilbert Julie,Crider Christine D.,Steinbock Kyle A.,Paulson Thomas C.,Anderson Layla A.,Kampe Christy,Johnson Jakea,Short Laura L.,Ezzell Lauren J.,Whitsett Margaret E.,McHenry Rendie E.,Hargrave Samarian J.,Blair Marica,Luther Jennifer L.,Pulido Claudia Guevara,Peterson Bryan P. M.,LaRose Mary,Landreth Leigha,Hicks Madeline,Parks Lisa,Bongu Jahnavi,McDonald David,Cass Candice,Seiler Sondra,Park David,Hink Tiffany,Wallace Meghan,Burnham Carey-Ann,Arter Olivia G., ,

Publisher

Centers for Disease Control MMWR Office

Subject

Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology

Reference10 articles.

1. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings.;Thompson;N Engl J Med,2021

2. Association between mRNA vaccination and COVID-19 hospitalization and disease severity.;Tenforde;JAMA,2021

3. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.;Tartof;Lancet,2021

4. Food and Drug Administration. Coronavirus (COVID-19) update: FDA takes multiple actions to expand use of Pfizer-BioNtech COVID-19 vaccine. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-multiple-actions-expand-use-pfizer-biontech-covid-19-vaccine

5. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3